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Osteopenia and osteoporosis are frequent in HIV
infected patients, with a prevalence of 66% and 15%
reported in a metaanalysis. In an aging population, low
bone mineral density (BMD) will translate in fracture-
related morbidity and mortality over time. As a matter
of fact, increased fracture rates in HIV positive patients
have recently been reported, particularly if older than
40-50 years. The etiology of low BMD is multifactorial.
HIV independent risk factors may thereby overweight
HIV dependent and treatment related factors. Low BMI,
malnutrition, vitamin D deficiency, substance abuse,
hypogonadism, physical inactivity or osteotoxic medica-
tion (e.g. steroids), chronic liver or kidney disease are
overrepresented in many HIV positive populations. HIV
positivity correlates with increased bone turnover. Viral
replication results in continuous cytokine production
that directly and indirectly (through RANKL) activates
osteoclasts. On the other hand, SMART and several
other studies have correlated cART initiation with accel-
erated bone loss irrespective of the regimen used.
Remarkably, this effect stabilized within the first year of
treatment and might thus be related to IRIS. Most, but
not all, associations of bone loss with protease inhibitor
treatment disappeared after correction for HIV-indepen-
dent risk factors for low BMD, in particular low BMI.
Upon Tenofovir initiation, a similar pattern has been
observed even in switch studies with suppressed viremia.
Again, these findings normalized within a year. Based on
a concomitant increase in serum alkaline phosphatase
and PTH levels, osteomalacia secondary to drug-related
renal phosphate wasting has been postulated, but lacks
strong evidence. Still, monitoring of phosphatemia and
the correction of vitamin D deficiency has been sug-
gested for Tenofovir-treated patients.
Taken together, HIV positive patients carry a relevant
risk for low-impact fractures. This merits a systematic
assessment of risk factors for low BMD and falls. Given
that a prevalent vertebral fracture indicates an equal risk
for a subsequent fracture as documented osteoporosis,
particular attention should be paid to identify subclinical
fractures. For patients aged over 40, FRAX® can be used
to identify patients qualifying for bone density measure-
ment (DXA) or biphosphonate treatment according to
national guidelines. HIV may thereby be considered as a
secondary cause of osteoporosis.
Published: 8 November 2010
doi:10.1186/1758-2652-13-S4-O41
Cite this article as: Fux: What affects the bone in our HIV-positive
patients? Journal of the International AIDS Society 2010 13(Suppl 4):O41.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submitUniversitätsklinik fur Infektiologie, Inselspital, Bern, Switzerland
Fux Journal of the International AIDS Society 2010, 13(Suppl 4):O41
http://www.jiasociety.org/content/13/S4/O41
© 2010 Fux; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
